Sept 24 (Reuters) -

UniQure's ( QURE ) experimental gene therapy significantly

slowed the progression of a brain disorder in an early-to-mid

stage study, it said on Wednesday.

Trading of the company's U.S.-listed shares were halted

in premarket.

The therapy, called AMT-130, reduced disease progression by

75% at 36 months in patients who received a high dose, based on

a widely used clinical scale.

UniQure ( QURE ) is developing the drug to treat Huntington's

disease, a rare inherited brain disorder that gradually impairs

movement, thinking, and behavior, and eventually leads to severe

disability and death.